
Ask a doctor about a prescription for IVABRADINE VIATRIS 5 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Ivabradina Viatris 5 mg Film-Coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Ivabradina is a heart medicine used to treat:
About stable angina (usually known as “angina”)
Stable angina is a heart disease that occurs when the heart does not receive enough oxygen. It usually appears between the ages of 40 and 50. The most frequent symptom of angina is chest pain or discomfort. Angina is more likely to occur when the heart beats faster in situations such as exercise, emotion, exposure to cold, or after eating. This increase in heart rate can cause chest pain in people with angina.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when your heart cannot pump enough blood to the rest of the body. The most frequent symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
Ivabradine works mainly by reducing the heart rate by some beats per minute. This reduces the heart's need for oxygen, especially in situations where an angina attack is more likely to occur. In this way, ivabradine helps control and reduce the number of angina attacks.
Also, since a high heart rate affects the functioning of the heart and vital prognosis in patients with chronic heart failure, the specific heart rate-lowering action of ivabradine helps improve heart function and vital prognosis in these patients.
Do not take Ivabradina Viatris
Warnings and precautions
Consult your doctor or pharmacist before starting to take ivabradina Viatris:
If you meet any of these conditions, consult your doctor immediately before or during treatment with ivabradina.
Children and adolescents
Ivabradina tablets are not intended for use in children and adolescents under 18 years of age.
Other medicines and Ivabradina Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Make sure to inform your doctor if you are taking any of the following medicines, as it may be necessary to adjust the dose of ivabradine or monitor:
Taking Ivabradina Viatris with food and drinks
Avoid grapefruit juice during treatment with ivabradina.
Pregnancy and breast-feeding
Do not take Ivabradina tablets if you are pregnant or plan to become pregnant (see “Do not take Ivabradina Viatris”).
If you are pregnant and have taken ivabradina, consult your doctor.
Do not take ivabradina if you are of childbearing age and are not using reliable contraceptive methods (see “Do not take Ivabradina tablets”).
Do not take ivabradina if you are breast-feeding (see “Do not take Ivabradina Viatris”). Talk to your doctor if you are breast-feeding or plan to start breast-feeding, as breast-feeding should be interrupted if you are taking ivabradina.
If you are pregnant or breast-feeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
Ivabradina may cause transient visual phenomena (a brief increase in brightness, see “Possible side effects”). If this happens to you, be careful when driving or using machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
This medicine contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; this is essentially “sodium-free”.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Ivabradina tablets should be taken with breakfast and dinner.
The 5 mg tablet can be divided into two equal doses.
If you are being treated for stable angina
The initial dose should not exceed one 5 mg ivabradine tablet twice a day. If you still have symptoms of angina and if you have tolerated the 5 mg dose twice a day well, the dose can be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (for example, if you are an elderly person), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you are being treated for chronic heart failure
The recommended initial dose is one 5 mg ivabradine tablet twice a day, which can be increased, if necessary, to one 7.5 mg ivabradine tablet twice a day. Your doctor will decide the suitable dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (for example, if you are an elderly person), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you take more Ivabradina Viatris than you should
An overdose of ivabradine tablets may make you feel tired or have difficulty breathing, because your heart is beating too slowly. If this happens, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Ivabradina Viatris
If you forget to take a dose of ivabradine tablets, take the next dose at the scheduled time. Do not take a double dose to make up for forgotten doses.
The printed calendar on the blister pack containing the tablets will help you remember when you last took an Ivabradina tablet.
If you stop taking Ivabradina Viatris
Generally, treatment for angina pectoris or chronic heart failure is for life, so you should consult your doctor before stopping this medicine.
If you think the action of ivabradine is too strong or too weak, tell your doctor or pharmacist.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most frequent adverse reactions with this medicine are dose-dependent and are related to its mechanism of action:
Very common (may affect more than 1 in 10 people):
Transient visual phenomena (brief moments of increased brightness, usually caused by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These usually appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Common (may affect up to 1 in 10 people):
Modification of heart function (the symptoms are a slowing of the heart rate). This occurs, especially, in the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Common (may affect up to 1 in 10 people):
Rapid irregular heart contraction, sensation of abnormal heartbeat, uncontrolled high blood pressure, headache, dizziness, and blurred vision (cloudy vision).
Uncommon (may affect up to 1 in 100 people):
Palpitations and extra heartbeats, sensation of dizziness (nausea), constipation, diarrhea, abdominal pain, sensation of spinning (vertigo), difficulty breathing (dyspnea), muscle cramps, changes in laboratory tests: elevated blood uric acid levels, an excess of eosinophils (a type of white blood cell), and elevated creatinine levels in the blood, skin rash, angioedema (such as swelling of the face, tongue, or throat, difficulty breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal electrocardiogram, double vision, visual disturbance.
Rare (may affect up to 1 in 1,000 people):
Hives, itching, skin redness, malaise.
Very rare (may affect up to 1 in 10,000 people):
Irregular heartbeats.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, the blister pack, and the tablets, after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Do not use the medicine packaged in bottles for more than 6 months after its first opening.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Each film-coated tablet contains 5 mg of ivabradine (equivalent to 5.961 mg of ivabradine as oxalate).
Ivabradina Viatris 5 mg are film-coated tablets of yellow color, round, marked with "5" on one side and with a score line on the other. The tablet can be divided into equal doses.
The tablets are available in packs containing continuous PVC/PE/PVdC-Aluminum blisters of 14, 14x1, 28, 56, 56x1, 98, and 112 film-coated tablets, and in packs containing unit-dose PVC/PE/PVdC-Aluminum blisters of 14 and 56 film-coated tablets.
The tablets are available in packs containing continuous Aluminum-Aluminum blisters of 14, 28, 56, and 98 film-coated tablets, and in packs containing unit-dose Aluminum-Aluminum blisters of 14 and 56 film-coated tablets.
The tablets are available in calendar blisters packs (Aluminum-Aluminum; PVC/PE/PVdC-Aluminum) of 28, 56, 98 film-coated tablets.
The tablets are available in HDPE bottles of 56, 98, 100 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
HBM Pharma s.r.o
Sklabinská 30
03680 Martin
Slovakia
Delorbis Pharmaceuticals Ltd
17, Athinon str., Ergates Industrial Area
2643 Ergates
Nicosia
Cyprus
Further information about this medicinal product can be obtained from the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Germany: Ivabradin Mylan 5 mg Filmtabletten
Bulgaria: Ivabradine Mylan 5 mg film-coated tablets
Spain: Ivabradina Viatris 5 mg film-coated tablets EFG
Slovenia: Ivabradine Mylan 5 mg film-coated tablets
Slovakia: Ivabradín Mylan 5 mg
Estonia: Ivabradine Mylan
France: Ivabradine Mylan
Hungary: Ivabradine Mylan
Ireland: Ivabradine Mylan
Italy: Ivabradina Mylan Pharma
Latvia: Ivabradine Mylan
Lithuania: Ivabradine Mylan
Netherlands: Ivabradine Mylan 5 mg, film-coated tablets
Poland: Ivabradine Mylan
Portugal: Ivabradina Mylan
United Kingdom: Ivabradine 5 mg film-coated tablets
Romania: Ivabradina Mylan 5 mg film-coated tablets
Date of the last revision of this leaflet:February 2021.
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of IVABRADINE VIATRIS 5 mg FILM-COATED TABLETS in October, 2025 is around 28.85 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IVABRADINE VIATRIS 5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.